Comparative analysis of treatment modalities for solitary, small (≤3 cm) hepatocellular carcinoma: A systematic review and network meta-analysis of oncologic outcomesUniv Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Westmead Hosp, Dept Surg, Sydney, Australia..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Ottawa, Dept Med, Ottawa, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Toronto, Dept Surg, Toronto, ON, Canada.;Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Univ Toronto, Dept Surg, Toronto, ON, Canada.;Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada.;Mayo Clin Rochester, Dept Surg, Rochester, MN USA..
Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada.;Univ Bern, Univ Hosp Bern, Dept Visceral Surg & Med, Inselspital, Bern, Switzerland..
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada..
Toronto Gen Hosp, Div Gastroenterol & Hepatol, Toronto, ON, Canada..
Trinity Coll Dublin, Trinity St Jamess Canc Inst, Trinity St Jamess Canc Inst, Dublin 8, Ireland..
Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands..
Univ Toronto, Dept Surg, Toronto, ON, Canada.;Univ Hlth Network, HPB Surg Oncol, Toronto, ON, Canada..
Show others and affiliations
2025 (English)In: Surgery, ISSN 0039-6060, E-ISSN 1532-7361, Vol. 180, article id 108917Article, review/survey (Refereed) Published
Abstract [en]
Background
Solitary hepatocellular carcinoma measuring ≤3 cm represents approximately 30% of hepatocellular carcinoma cases, yet treatment guidelines lack robust evidence. This study compares oncologic outcomes after ablation, liver resection, and liver transplantation for solitary, small hepatocellular carcinoma.
Methods
We systematically searched databases up to 7 February 2022, for studies including adults with solitary hepatocellular carcinoma ≤3 cm treated by any ablation, liver resection, or liver transplantation. We excluded non-hepatocellular carcinoma cancers, recurrent/metastatic diseases, and alternative therapies. A frequentist network meta-analysis assessed 5-year overall survival and recurrence-free survival using only adjusted effect estimates while accounting for bias risk.
Results
We identified 80 studies (4 randomized controlled trials, 72 retrospectives, and 4 prospective cohorts) with 28,211 patients. In the network meta-analysis for 5-year overall survival (26 studies), liver transplantation was associated with the lowest mortality hazard (hazard ratio, 0.47; 95% confidence interval, 0.31–0.73, referenced to liver resection), followed by liver resection (reference), whereas ablation had the greatest mortality hazard (hazard ratio, 1.32; 95% confidence interval, 1.16–1.49, referenced to liver resection). For 5-year recurrence-free survival (19 studies), liver transplantation had the best outcome (hazard ratio, 0.36; 95% confidence interval, 0.20–0.63, referenced to liver transplantation), followed by liver resection (reference), with ablation showing the least favorable outcome (hazard ratio, 1.67; 95% confidence interval, 1.45–1.93, referenced to liver resection).
Conclusions
This network meta-analysis provides the evidence for comparing treatment modality outcomes for solitary, small (≤3 cm) hepatocellular carcinoma. LT emerges as the superior choice for achieving a better 5-year OS, followed by liver resection, then ablation. When feasible to preserve liver function, liver resection can be prioritized. Ablation with close surveillance should be reserved for individuals unfit for surgery.
Place, publisher, year, edition, pages
Elsevier, 2025. Vol. 180, article id 108917
National Category
Surgery Cancer and Oncology Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-554745DOI: 10.1016/j.surg.2024.10.008ISI: 001455707100001PubMedID: 39609218Scopus ID: 2-s2.0-85210394104OAI: oai:DiVA.org:uu-554745DiVA, id: diva2:1952762
2025-04-162025-04-162025-04-16Bibliographically approved